KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Bio-Rad Laboratories (BIO) EBIAT (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed EBIAT for 17 consecutive years, with $720.0 million as the latest value for Q4 2025.

  • Quarterly EBIAT rose 200.59% to $720.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $759.9 million through Dec 2025, up 141.2% year-over-year, with the annual reading at $759.9 million for FY2025, 141.2% up from the prior year.
  • EBIAT for Q4 2025 was $720.0 million at Bio-Rad Laboratories, up from -$341.9 million in the prior quarter.
  • The five-year high for EBIAT was $3.9 billion in Q3 2021, with the low at -$3.4 billion in Q1 2022.
  • Average EBIAT over 5 years is -$54.7 million, with a median of $87.6 million recorded in 2023.
  • The sharpest move saw EBIAT plummeted 443.6% in 2022, then skyrocketed 514.49% in 2024.
  • Over 5 years, EBIAT stood at -$1.6 billion in 2021, then soared by 152.65% to $827.7 million in 2022, then plummeted by 57.75% to $349.7 million in 2023, then tumbled by 304.69% to -$715.8 million in 2024, then soared by 200.59% to $720.0 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at $720.0 million, -$341.9 million, and $317.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.